IP Library Granted Patent US 10,196,383
Granted Patent B2
US 10,196,383 · App. 15/745,437 · Granted Feb 5, 2019

Substituted quinazoline compounds and preparation and uses thereof

Inventors: Yingjun Zhang (Dongguan, CN); Chuanfei Jin (Dongguan, CN); Jinheng Gao (Dongguan, CN); Ji Zhang (Dongguan, CN)
Assignee: SUNSHINE LAKE PHARMA CO., LTD.
C07D403/14A61K31/551A61K45/06A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,383
App. No.
15/745,437
Granted
Feb 5, 2019
Kind
B2
Abstract

The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.

Claims (26)

1. A compound having Formula (I) or a stereoisomer, an N-oxide, or a pharmaceutically acceptable salt,

wherein,

G is a 5-membered heterocycloalkyl or heteroaryl group containing at least one nitrogen, wherein G is optionally substituted with one or more R 8 ;

each R 1 is independently H, D, F, Cl, Br, I, OH, NH 2 , NO 2 , CN, N 3 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 alkylamino, C 3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C 6-10 aryl or 5- to 12-membered heteroaryl, wherein each R 1 is optionally and independently substituted with one or more R 8 ;

each R 2 is independently H, D, F, Cl, Br, I, OH, NH 2 , NO 2 , CN, N 3 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 hydroxyalkyl or C 1-4 haloalkyl;

each R 3 is independently H, D, F, Cl, Br, I, OH, NH 2 , NO 2 , CN, N 3 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C 6-10 aryl or 5- to 12-membered heteroaryl, —(CR 4 R 4a ) q —OR 7 , —(CR 4 R 4a ) q —NR 5 R 6 , —(CR 4 R 4a ) q S(═O) r R 7 , —(CR 4 R 4a ) q S(═O) 2 NR 5 R 6 , —(CR 4 R 4a ) q C(═O)R 7 , —(CR 4 R 4a ) q OC(═O)R 7 , —(CR 4 R 4a ) q C(═O)OR 7 , —(CR 4 R 4a ) q —N(R 5 )C(═O)R 7 , —C(═NR 7 )NR 5 R 6 , —N(R 7 )C(═O)NR 5 R 6 , —(CR 4 R 4a ) q —N(R 5 )S(═O) r R 7 or —(CR 4 R 4a ) q C(═O)NR 5 R 6 , wherein each R 3 is optionally and independently substituted with one or more R 8 ;

wherein each R 4 and R 4a is independently H, D, F, Cl, Br, I, CN, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 haloalkoxy, C 1-4 haloalkylamino, C 3-8 carbocyclyl, 3- to 8-membered heterocyclyl, C 6-10 aryl or 5- to 6-membered heteroaryl;

each R 5 , R 6 and R 7 is independently H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkenyl, C 3-8 carbocyclyl, (C 3-6 cycloalkyl)-(C 1-4 alkylene)-, 3- to 8-membered heterocyclyl, (3- to 6-membered heterocyclyl)-(C 1-4 alkylene)-, phenyl, (C 6-10 aryl)-(C 1-4 alkylene)-, 5- to 6-membered heteroaryl or (5- to 6-membered heteroaryl)-(C 1-4 alkylene)-, or R 5 and R 6 together with the nitrogen atom to which they are attached, independently and optionally form 3- to 6-membered heterocyclyl, wherein each C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl and C 3-8 carbocyclyl is optionally and independently substituted with one or more substituents independently selected from D, F, Cl, Br, OH, NH 2 , CN, N 3 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 alkylamino;

each R 8 is independently H, D, F, Cl, Br, I, ═O, OH, NH 2 , NO 2 , CN, N 3 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl or C 1-4 haloalkylamino;

each m and n is independently 0, 1, 2, 3, or 4;

t is 0 or 1;

p is 0, 1, 2, 3, 4, or 5;

each r is independently 0, 1 or 2; and

each q is independently 0, 1, 2, 3, or 4.

2. The compound of claim 1 , wherein G is:

and G is optionally substituted with one or more R 8 .

3. The compound of claim 1 , wherein each R 1 is independently H, D, F, Cl, Br, I, OH, NH 2 , NO 2 , CN, N 3 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 hydroxyalkyl, C 1-4 alkylamino, C 3-8 carbocyclyl, 3- to 8-membered heterocyclyl, C 6-10 aryl or 5- to 6-membered heteroaryl, wherein each R 1 is optionally and independently substituted with one or more R 8 .

4. The compound of claim 1 , wherein each R 1 is independently H, D, F, Cl, Br, OH, NH 2 , NO 2 , CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, vinyl, ethynyl, methoxy, ethoxy, methylamino, ethylamino, hydroxymethyl, hydroxyethyl, trifluoromethyl, cyclopropyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrrolyl, imidazolyl, thiazolyl or thienyl.

5. The compound of claim 1 , wherein each R 2 is independently H, F, Cl, OH, NH 2 , NO 2 , CN, methyl, ethyl, n-propyl, isopropyl, vinyl, allyl, propargyl, methoxy, ethoxy, methylamino, ethylamino, hydroxymethyl, hydroxyethyl or trifluoromethyl.

6. The compound of claim 1 , wherein each R 3 is independently H, D, F, Cl, Br, I, OH, NH 2 , NO 2 , CN, N 3 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 carbocyclyl, 3- to 8-membered heterocyclyl, C 6-10 aryl, 5- to 6-membered heteroaryl, —(CR 4 R 4a ) q —OR 7 , —(CR 4 R 4a ) q —NR 5 R 6 , —(CR 4 R 4a ) q S(═O) r R 7 , (CR 4 R 4a ) q S(═O) 2 NR 5 R 6 , —(CR 4 R 4a ) q C(═O)R 7 , —(CR 4 R 4a ) q OC(═O)R 7 , —(CR 4 R 4a ) q C(═O)OR 7 , —(CR 4 R 4a ) q —N(R 5 )C(═O)R 7 , —C(═NR 7 )NR 5 R 6 , —N(R 7 )C(═O)NR 5 R 6 , —(CR 4 R 4a ) q —N(R 5 )S(═O) r R 7 or —(CR 4 R 4a ) q C(═O)NR 5 R 6 , wherein each R 3 is optionally and independently substituted with one or more R 8 .

7. The compound of claim 1 , wherein each R 3 is independently H, D, F, Cl, Br, OH, NH 2 , NO 2 , CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, vinyl, ethynyl, methoxy, ethoxy, methylamino, ethylamino, hydroxymethyl, hydroxyethyl, trifluoromethyl, cyclopropyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrrolyl, imidazolyl, thiazolyl, thienyl, —C(═O)NH 2 or —COOH.

8. The compound of claim 1 , wherein each R 4 and R 4a is independently H, D, F, Cl, Br, I, CN, methyl, ethyl, isopropyl, vinyl, allyl, ethynyl, propargyl, methoxy, tert-butoxy, methylamino, —OCF 3 , —NHCF 3 , cyclopentyl, cyclohexyl, piperidin-1-yl, piperazin-1-yl, pyridin-2-yl, phenyl or naphthyl; and

each R 5 , R 6 and R 7 is independently H, methyl, ethyl, isopropyl, vinyl, allyl, ethynyl, propargyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, piperidin-1-yl, piperazin-1-yl, imidazol-1-yl, pyridin-4-yl-methyl, phenyl or benzyl, or R 5 and R 6 together with the nitrogen atom to which they are attached, form pyrrolidinyl, piperazinyl, imidazolidinyl or morpholinyl.

9. The compound of claim 1 , wherein each R 8 is independently H, D, F, Cl, Br, I, ═O, OH, NH 2 , NO 2 , CN, N 3 , methyl, ethyl, ethynyl, propynyl, methoxy, tert-butoxy, methylamino, trifluoromethyl, trifluoromethoxy, hydroxymethyl or trifluoromethylamino.

10. The compound of claim 1 having one of the following structures:

11. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
To: SUNSHINE LAKE PHARMA CO., LTD.
Reel/Frame 052921/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2019
From: SUNSHINE LAKE PHARMA CO., LTD.
To: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
Reel/Frame 050832/0688 →
CORRECTIVE ASSIGNMENT TO CORRECT THE POSTAL CODE OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 045078 FRAME 0587. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 20, 2018
From: ZHANG, YINGJUN; JIN, CHUANFEI; ZHANG, JI; GAO, JINHENG
To: SUNSHINE LAKE PHARMA CO., LTD.
Reel/Frame 047603/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2018
From: ZHANG, YINGJUN; JIN, CHUANFEI; GAO, JINHENG; ZHANG, JI
To: SUNSHINE LAKE PHARMA CO., LTD.
Reel/Frame 045078/0587 →
Priority Claims (1)
CN 2015 1 0424521 · Jul 17, 2015 · national
Continuity (1)
Related Publication 20180215737A1 · Aug 2, 2018
Cited By (2)
US 12,201,634 US 12,378,254